Edwards Lifesciences Intrinsic Value – Dynamic Advisor Solutions LLC Reduces Stake in Edwards Lifesciences Co.
December 23, 2023
☀️Trending News
Dynamic Advisor Solutions LLC recently confirmed that it has reduced its holdings in Edwards Lifesciences ($NYSE:EW) Co. Edwards Lifesciences is a medical device company that specializes in the development, manufacturing, and distribution of products related to cardiology and heart health. It focuses on the design, manufacture, and distribution of innovative products and technologies that enable clinicians to treat structural heart disease and critical care patients. The company’s products are used in a variety of clinical settings, including hospitals, ambulatory surgery centers, and other healthcare facilities. Its product portfolio includes transcatheter heart valve replacement systems, surgical heart valves, tissue valves, and associated delivery systems, as well as percutaneous coronary intervention products.
Additionally, Edwards Lifesciences offers products for monitoring hemodynamic parameters in intensive care units, as well as products for monitoring the cardiovascular system.
Share Price
Dynamic Advisor Solutions LLC recently reduced its stake in Edwards Lifesciences Co., a medical technology company that provides products and technologies for structural heart disease and critical care monitoring. On Friday, the stock opened at $75.3 and closed at $75.8, up by 1.2% from its last closing price of 75.0. This increase in stock price indicates that investors remain confident in the company’s product offerings and financial health. Despite the reduction in stake, analysts remain positive about the potential of Edwards Lifesciences Co.’s products and financial performance in the long run. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Edwards Lifesciences. More…
| Total Revenues | Net Income | Net Margin |
| 5.82k | 1.43k | 27.1% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Edwards Lifesciences. More…
| Operations | Investing | Financing |
| 1.04k | 254.4 | -1.14k |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Edwards Lifesciences. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 9.37k | 2.64k | 10.98 |
Key Ratios Snapshot
Some of the financial key ratios for Edwards Lifesciences are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 10.0% | 10.3% | 30.0% |
| FCF Margin | ROE | ROA |
| 13.5% | 16.7% | 11.6% |
Analysis – Edwards Lifesciences Intrinsic Value
GoodWhale has conducted an in-depth analysis of EDWARDS LIFESCIENCES‘s wellbeing. Our proprietary Valuation Line has calculated the fair value of EDWARDS LIFESCIENCES share to be around $104.2. However, the current stock price of EDWARDS LIFESCIENCES is priced at $75.8, which is a 27.3% undervaluation. This presents a great opportunity for investors to buy EDWARDS LIFESCIENCES’ stock at a discounted price. More…
Peers
Edwards Lifesciences Corp is a global leader in the development of products and technologies to treat cardiovascular disease. The company’s products are used by healthcare professionals to treat patients suffering from cardiac and vascular diseases. Edwards Lifesciences Corp’s competitors include Implanet SA, Avra Medical Robotics Inc, and Paragon 28 Inc.
– Implanet SA ($OTCPK:IMPZY)
Implanet SA is an orthopedic company that manufactures and distributes medical devices. The company has a market cap of 3.76M as of 2022 and a Return on Equity of -114.56%. The company’s products are used in the treatment of conditions such as osteoarthritis, degenerative disc disease, and deformities of the spine and extremities.
– Avra Medical Robotics Inc ($OTCPK:AVMR)
Avra Medical Robotics Inc is a publicly traded company with a market capitalization of 239.1 thousand dollars as of 2022. The company focuses on the development and commercialization of robotic technologies for use in minimally invasive surgery. The company’s primary product is the Avra Surgical System, a surgical robotics platform that assists surgeons in performing tasks such as suturing, tissue manipulation, and vessel sealing. The company has received FDA clearance for the Avra Surgical System and has CE Mark approval for the European Union.
– Paragon 28 Inc ($NYSE:FNA)
Paragon 28 Inc is a publicly traded company with a market capitalization of 1.33 billion as of 2022. The company has a negative return on equity of 9.25%. Paragon 28 Inc is engaged in the business of providing turnkey engineering, procurement and construction services to the oil and gas industry.
Summary
Dynamic Advisor Solutions LLC recently reduced its holdings in Edwards Lifesciences Corp., a global medical technology firm that specializes in advanced patient care solutions. The company’s share price has been bolstered by consistent revenue growth stemming from strong product sales, which have been driven by the company’s long-term strategy of expanding into new markets and developing competitively priced products. With a strong balance sheet and a history of successful capital allocation, Edwards Lifesciences is well-positioned to capitalize on future growth opportunities.
